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Mayo Clinic College of Medicine, Department of Internal Medicine, Rochester, MN, USASummary ﬂuids such as blood, urine, bile, saliva in vivo, or into culture med-Exosomes are small (30–100 nm in diameter) extracellular mem-
brane-enclosed vesicles released by different cell types into the
extracellular space or into biological ﬂuids by exocytosis as a
result of fusion of intracellular multivesicular bodies with the
plasma membrane. The primary function of exosomes is intercel-
lular communication with both beneﬁcial (physiological) and
harmful (pathological) potential outcomes. Liver cells are exo-
some-releasing cells as well as targets for endogenous exosomes
and exosomes derived from cells of other organs. Despite limited
studies on liver exosomes, initial observations suggest that these
vesicles are important in liver physiology and pathophysiology.
In this review, we brieﬂy summarize the recent ﬁndings on liver
exosomes, their functions and signiﬁcance for novel diagnostic
and therapeutic approaches.
 2013 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
A wide variety of cells release small (30–100 nm in diameter)
membrane-enclosed vesicles termed exosomes into the extracel-
lular milieu. Over the past several years, there has been increas-
ing interest in the biological properties and pathophysiological
relevance of these extracellular vesicles derived from liver cells,
principally hepatocytes and cholangiocytes. In this review, we
brieﬂy summarize the recent ﬁndings on liver exosomes, their
functions and signiﬁcance for novel diagnostic and therapeutic
approaches.Formation, composition, and functions of exosomes
Exosomes are derived from the internal vesicles of multivesicular
bodies (MVBs). While some MVBs are degraded in lysosomes,
other MVBs fuse with the plasma membrane and release their
content of microvesicles in an exocytic manner into biologicalJournal of Hepatology 20
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E-mail address: larusso.nicholas@mayo.edu (N.F. LaRusso).ium in vitro [1–3] (Fig. 1). The number of exosomes present in
biological ﬂuids is high; in serum, it is estimated to be about 3
million exosomes per microliter [3].
Morphologically by electron microscopy, exosomes typically
are vesicles with distinctive cup- or ‘‘deﬂated football’’-shaped
morphology (Fig. 1); the shape may reﬂect a collapse of vesicles
during sample preparation, because cryo-electron and scanning
electron microscopy show a perfectly rounded shape of isolated
exosomes (Fig. 1) [4]. Biochemically, exosomes contain common
‘‘marker’’ proteins (e.g., tetraspanins such as CD9, CD10, CD26,
CD53, CD63, CD81, CD82; endosome-associated proteins that
are involved in MVB biogenesis, Alix and TSG101; cytoplasmic
heat shock proteins, Hsc70 and Hsp90), and cell-type speciﬁc
proteins and nucleic acids including mRNAs, microRNAs (miR-
NAs) and other non-coding RNAs, the composition of which
depends on the functional state of the cells (e.g., rested, stimu-
lated, stressed, transformed, etc.) [1,3]. The estimated total cargo
per exosome is about 100 proteins and 10,000 net nucleotides [3].
As of January 2012, 11,261 proteins, 2375 mRNAs and 764 miR-
NAs have been identiﬁed in association with exosomes suggest-
ing their great heterogeneity and uniqueness [5].
The primary function of exosomes is intercellular communica-
tion; i.e., to shuttle various signaling molecules between neigh-
boring and distant cells [1–3]. Exosomes can interact with
target cells via unknown receptors, including receptors localized
to primary cilia, and activate downstream intracellular signaling
pathways [1–3,6]. They can also directly fuse with the cell mem-
brane integrating exosomal membrane proteins into the plasma
membrane or be endocytosed delivering their cargo into the cyto-
plasm of the recipient cells [1,3,4] (Fig. 2).
Exosomes are heterogenous in size and content and demon-
strate different biological effects and targeting speciﬁcities. They
can inﬂuence the immune system, act as signaling complexes,
transfer receptors from one cell to another, convey speciﬁc
mRNAs, miRNAs, and proteins into the cytoplasm of recipient
cells, and, as a result, impact numerous physiological processes
[2–4]. Exosomes also facilitate viral transport, spread cell dam-
age, and stimulate malignant transformation [4,7].Exosomes in liver physiology and disease
Both types of liver epithelia (i.e., hepatocytes and cholangio-
cytes), natural killer T (NKT) cells, hepatic stellate cells, adult liver13 vol. 59 j 621–625
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Fig. 2. Exosomes in intercellular signaling. (A) In the liver, exosomes derived from hepatocytes and cholangiocytes are transported by bile ﬂow to target cholangiocytes
with which they may interact via several mechanisms depending on their cargo and biological properties. They can fuse with the plasma membrane and deliver their
content into the cytoplasm of a target cell; interact with receptors on the apical plasma and ciliary membrane inducing intracellular signaling; and endocytosed for
recycling. (B and C) Biliary exosomes surround and attach to cholangiocyte cilia in mouse liver as viewed by TEM (B) and SEM (C), supporting the involvement of exosomes
and cilia in mechanisms of intercellular signaling. (B and C adapted from [6], with permission).
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Fig. 1. Exosome release. (A) Exosomes containing membrane and cytosolic proteins, mRNAs, and miRNAs, are derived from the multivesicular body (MVB) sorting
pathway. Membrane proteins are oriented in a fashion (extracellular region out) that permits profound biological autocrine and paracrine effects. (B) Exosomes isolated
from rat bile have a cup- or ‘‘deﬂated football’’-shaped morphology by transmission electron microscopy (TEM), but they have a perfectly round shape by scanning electron
microscopy (SEM). (C) In cholangiocytes of mouse liver, MVBs containing exosomes (arrows) (a) move to the apical plasma membrane (APM) (b), and release exosomes into
the bile duct lumen by exocytosis (c). (B and C adapted from [6], with permission).
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stem cells, and hepatic sinusoidal endothelial cells are
exosome-releasing and/or exosome-targeting cells [6,8–12].
Hepatocyte- and cholangiocyte-derived exosomes are involved
in hepatocyte-to-cholangiocyte, cholangiocyte-to-cholangiocyte
and cholangiocyte-to-hepatic sinusoidal endothelial cell commu-
nication [6,10]. Biliary exosomes affect the ERK signaling path-
way and miR-15a expression in cholangiocytes and inhibit their
proliferation [6]. Hepatic stellate cells and rat cholangiocytes
release exosomes containing biologically active Hedgehog ligands
and alter gene expression in target hepatic sinusoidal endothelial
cells [10]. Exosomes derived from mouse hepatocytes contain
several members of the cytochrome P450, UDP-glucuronosyl-
transferase and glutathione S-transferase drug-metabolizing pro-
tein families and are presumably involved in detoxiﬁcation of
drugs and endogenous toxic substances in target cells [9].
Liver cells are also targets for exosomes derived from the cells
of other organs and tissues. For example, exosomes derived from
the intestinal epithelial cells carry prostaglandin E2 and induce
liver immune tolerance by communicating directly with the liver
NTK cells via the Wnt/b-catenin signaling pathway [8].
To date, the information on the potential involvement of exo-
somes in liver diseases is limited to the pathogenesis of hepato-
cellular carcinoma (HCC) [13], viral hepatitis (HCV) [14] and
liver inﬂammation [15]. It has been reported that the human hep-
atoma cell line, Hep3B, releases exosomes containing a speciﬁc
subset of miRNAs that are taken up by an hepatocellular carci-
noma cell line, HepG2, resulting in inhibition of transforming
growth factor b activated kinase-1 (TAK1), loss of which has been
implicated in hepatocarcinogenesis [13]. A potential role for exo-
somes in viral hepatitis is supported by observations that the
exosomal pathway is required for release of HCV from infected
cells. Also, HCV envelope proteins are associated with exosomes,
and exosome-associated viral RNA is present in plasma of HCV-
infected patients [14]. The role of exosomes in liver inﬂammation
is suggested from a study demonstrating that repeated injection
of exosomes isolated from peripheral blood of mice fed a high-fat
diet to mice fed a regular diet resulted in accumulation in the
liver of activated immature myeloid cells, CD11b+Ly6ChiLy6G-,
that caused chronic inﬂammation and promoted obesity-related
disorders, such as fatty liver disease [15].Liver exosomes as diagnostic and prognostic biomarkers
Currently, exosomes from urine and blood are considered as non-
invasive (urine) and minimally invasive (blood) sources of molec-
ular biomarkers for early detection and prognosis of various dis-
eases, including diseases of the liver [3]. This approach is based
on the observations that exosomes present in blood and urine
contain speciﬁc proteins, mRNAs and miRNAs derived from mul-
tiple organs, including liver, and that the exosomal cargo may be
associated with a given disease [16,17]. For example, in animal
models of liver injury that resemble liver damage in viral hepati-
tis, changes in the abundance and content of liver-derived exo-
somes were observed in both blood and urine. In particular, in
D-galactosamine (DGAL)-treated rats (an animal model for acute
liver injury), the number of CD10-, CD26-, and CD81-positive uri-
nary exosomes was dramatically reduced [17]. In the same DGAL
model and in acetaminophen-treated rats, the level of exosome-
associated liver-speciﬁc mRNA in serum was increased and this
increase correlated with evidence of liver injury [i.e., alanineJournal of Hepatology 201(ALT) and aspartate (AST) aminotransferase levels]. The compar-
ative analysis of exosomal liver-speciﬁc mRNAs with serum
transaminases indicated that mRNAs were more speciﬁc and
more sensitive biomarkers of liver injury [16]. The serum levels
of hepatocyte-derived exosome-associated miR-122, miR-148a,
and miR-194 were elevated in patients with liver injury due to
acute rejection after liver transplantation; importantly, their lev-
els appeared to rise earlier than aminotransferase levels [18].
Another example of the potential usefulness of exosomes as
biomarkers of disease is assessing exosomal miRNAs as an indica-
tion of hepatocyte injury in alcoholic, drug-induced, and inﬂam-
matory liver diseases [19]. An increase in exosomal miR-122,
which is abundant in hepatocytes, and miR-155, which regulates
inﬂammation in immune cells, was observed in the serum of
mouse models of alcoholic liver disease, drug-induced liver
injury, and Toll-like receptor ligand-induced inﬂammatory cell-
mediated liver damage. A characteristic expression of these two
miRNAs allowed differentiation between hepatocyte injury and
inﬂammation [19]. The miR-17-92 cluster, especially miR-92a, is
markedly overexpressed in HCC, and is associated with cancer
development and progression. On the other hand, the relative
amount of exosomal miR-92a is signiﬁcantly decreased in the
plasma of HCC patients compared with healthy donors. Although,
the pathophysiological signiﬁcance of the decrease of miR-92a in
plasma is still unknown, deregulation of miR-92a expression in
cells and plasma is implicated in the development of HCC, and
the level of exosomal miR-92a in plasma is considered as a poten-
tial diagnostic marker of HCC [7].
An increase in the level of CD10 protein was observed in uri-
nary exosomes obtained from glycine N-methyltransferase
knockout mice, an animal model of chronic liver injury associated
with steatosis, ﬁbrosis, and HCC. The increased level of CD10 pro-
tein was detected in very early disease stages and was consis-
tently observed over time course of disease progression [17].
An increase of CD81 protein in serum exosomes of patients with
chronic HCV was presumably associated with inﬂammation and
severity of ﬁbrosis [20]. The summary of recent observations on
exosomes as promising diagnostic and prognostic biomarkers in
liver diseases is shown in Table 1.Exosomes as novel therapeutics for liver diseases
Recently, progress has been made in developing novel, exosome-
based therapeutic approaches for treating different types of can-
cer [3], including liver tumors. Based on observations that exo-
somes released by HCC cells under stress condition contain
heat shock proteins (HSPs) that can improve tumor immunoge-
nicity and induce NKT cell antitumor responses, the potential
use of HSP-bearing exosomes for immunotherapy of HCC was
proposed [21]. Exosomes derived from human adult liver stem
cells (HLSC) inhibited the growth and survival of HepG2 and pri-
mary HCC cells in vitro by delivering antitumor miRNAs [12].
HLSC-derived exosomes also induced proliferation and apoptosis
resistance of human and rat hepatocytes in vitro and accelerated
the morphological and functional recovery of the rat liver in a
model of 70% hepatectomy in vivo, by delivering a speciﬁc subset
of 35 mRNAs that are associated with the regulation of transcrip-
tion, translation, proliferation, and apoptosis of target cells [22].
Exosomes derived from human umbilical cord mesenchymal
stem cells relieved liver ﬁbrosis induced by carbon tetrachloride3 vol. 59 j 621–625 623
Table 1. Exosomes as biomarkers of liver diseases.
Liver disease Source of 
exosomes
Exosomal cargo Observation Reference
Liver injury induced by DGAL Urine CD10, CD26, CD81 Decreased number of exosomes [17]
Liver injury associated with steatosis, Urine CD10 Increased number of exosomes [17]
HCV Serum CD81 Increased number of exosomes [20]
Liver injury induced by DGAL/APAP Serum Increased number of exosomes [16]
Liver injury/rejection Serum miR-122, miR-148a, miR-194 Increased number of exosomes [18]
Alcoholic, drug-induced, Serum, 
plasma
miR-122, miR-155 Increased number of exosomes [19]
HCC Plasma miR-92a Decreased number of exosomes [7]
fibrosis, HCC
inflammatory liver diseases
Liver-specific mRNAs
DGAL, D-galactosamine; APAP, acetaminophen; HCC, hepatocellular carcinoma; HCV, viral hepatitis.
Table 2. Exosomes as therapeutics in liver diseases.
Liver disease Donor cells Exosomal 
cargo
Target cells Application Outcome [Ref.]
HCC HCC cells Heat shock 
proteins
NKT cells HCC Improve tumor immunogenicity, induce 
NKT cell antitumor response
[21]
HCC Human adult liver stem cells Antitumor 
miRNAs
HepG2, primary  HCC 
cells, hepatocytes
HCC Inhibit the growth and survival of HCC 
cells, induce proliferation and apoptosis 
of human and rat hepatocytes
[12, 22]
CCL4-
induced 
Human umbilical cord 
mesenchymal stem cells
Unknown Hepatocytes
and collagen 
deposition
lagen deposition
[23]
HCV HuH7, HuH6, HepG2, 
hepatocytes
miRNA, 
siRNAs
HuH7, HuH6, HepG2, 
hepatocytes
HCV Exchange exosomes with potential 
therapeutic effects
[11]
Liver cancer Murine bone marrow 
stromal cells pulsed with 
homologous tumor-derived 
exosomes
Unknown Liver cancer cells Liver cancer Antitumor effect [2]
fibrotic liver
Hepatic inflammation Alleviate hepatic inflammation and col-
Clinical Application of Basic Science(CCL4)when theywere administered into themouse ﬁbrotic liver for
4 hours. As a result of such treatment, the surface ﬁbrous capsules
were reduced, their textures softened, hepatic inﬂammation and col-
lagen depositionwere reduced, and collagen type I and III decreased.
These changes and the recovered levels of serum AST suggested a
positive therapeutic effect of exosomes on ﬁbrotic liver [23].
Human hepatoma cells HuH7, stably transfected with small
interfering RNA (siRNA) against viral entry receptor CD81, release
siRNA-containing exosomes which in cell co-culture experiments
shuttle this siRNA to non-transfected HuH7 cells inhibiting CD81
expression in target cells. The shuttling of exosomes containing
exogenous siRNA between liver cells in vivo was demonstrated in
immunodeﬁcient NOD/SCID mice engrafted with human hepa-
toma cells producing CD81 siRNA. Exosomes containing this siRNA
were released byhumanhepatoma cells and caused suppression of
CD81 expression in target hepatocytes. This observation suggests
the potential use of exosomes containing siRNAs in RNA interfer-
ence-based therapies against HCV and other liver diseases [11].
It has been also demonstrated that murine bone marrow stro-
mal cells pulsed with homologous tumor-derived exosomes inhi-
bit proliferation of liver cancer cells, suggesting the potential use
of exosomes as a novel antitumor treatment [24]. The summary
of recent observations on exosomes as potential novel therapeu-
tics in liver diseases is presented in Table 2.
There are several other potential approaches for the use of
exosomes in therapeutic applications for liver diseases including:
(i) engineering exosomes containing speciﬁc biomolecules or624 Journal of Hepatology 201small molecule drugs and delivering them to the target cells;
(ii) monitoring the efﬁcacy of treatment by using exosomes as
molecular biomarkers of disease development, progression and
cure; and (iii) stimulating the release of exosomes containing
unneeded or harmful molecules.
Key Points 
• Exosomes are small membrane-enclosed vesicles
released by cells into the extracellular space or into
biological fluids 
• Exosomes containing cell-type specific proteins, 
mRNAs, and miRNAs are involved in intercellular
communication by delivering their cargo to the recipient
cells
• Liver cells are exosome-releasing and exosome-
targeting cells 
• Exosomes contribute to the pathogenesis of 
hepatocellular carcinoma, viral hepatitis, and hepatic
inflammation
• Exosomes hold great potential as diagnostic and 
prognostic molecular biomarkers of liver diseases and
as novel therapeutic modalities3 vol. 59 j 621–625
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Conclusions
As this review outlines, exosomes are important molecular enti-
ties involved in cell-to-cell communication within the liver, con-
tributing to liver physiology and pathophysiology. Exosomes also
hold great potential as novel diagnostic and prognostic molecular
biomarkers of liver diseases and as novel therapeutic modalities.
However, although signiﬁcant advances have been made, many
questions remain. Very little is known about the precise molecu-
lar mechanisms of exosome biogenesis, release, targeting, and
interactions with target cells within the liver. The existing data
also suggest that liver exosomes are heterogenous vesicles
derived from different hepatic cell types and, because of their
heterogeneity, likely perform speciﬁc functions in liver health
and disease that remain to be clariﬁed.Financial support
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